Development of active and passive human vaccines to treat methamphetamine addiction

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 206-213

  Gentry, W Brooks ^a   Rüedi Bettschen, Daniela ^a   Owens, S Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Addiction; Amphetamines; Drug abuse; Methamphetamine; Monoclonal antibody; Vaccines

Indexed keywords

ANTIBODY; HAPTEN; METHAMPHETAMINE; METHAMPHETAMINE VACCINE; PHENCYCLIDINE ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ADDICTION; ANTIBODY AFFINITY; ANTIBODY RESPONSE; BINDING SITE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LOCOMOTION; METHAMPHETAMINE ABUSE; METHAMPHETAMINE DEPENDENCE; NONHUMAN; PASSIVE IMMUNIZATION; PHARMACOLOGICAL BLOCKING; REVIEW; TREATMENT INDICATION;

ANTIBODIES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNIZATION, PASSIVE; METHAMPHETAMINE; SUBSTANCE-RELATED DISORDERS; VACCINATION; VACCINES, CONJUGATE;

EID: 67650449269     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.7456     Document Type: Review

References (72)

1. Office of Applied Studies S. The DASIS Report, "Trends in Methamphetamine/Amphetamine Admissions to Treatment: 1993-2003".
2. NACO. The Meth Epidemic in America. The National Association of Counties 2005.
3. Albertson TE, Derlet RW, Van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. West J Med 1999; 170:214-9.
4. Burns RS, Lerner SE. Perspectives: acute phencyclidine intoxication. Clin Toxicol 1976; 9:477-501.
5. Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994; 24:68-76.
6. Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, Derlet RW. Methamphetamine abuse and emergency department utilization. West J Med 1999; 170:198-202.
7. Glantz JC, Woods JR Jr. Cocaine, heroin, and phencyclidine: obstetric perspectives. Clin Obstet Gynecol 1993; 36:279-301.
8. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR. Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 1997; 282:834-8.
9. Kitayama S, Dohi T. Cellular and molecular aspects of monoamine neurotransmitter transporters. Jpn J Pharmacol 1996; 72:195-208.
10. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001; 39:32-41.
11. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005; 75:406-33.
12. Ellinwood EH Jr, Kilbey MM. Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants. Biol Psychiatry 1980; 15:749-57.
13. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996; 93:5166-71.
14. Henry JP, Botton D, Sagne C, Isambert MF, Desnos C, Blanchard V, et al. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J Exp Biol 1994; 196:251-62.
15. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH. Differential expression of two vesicular monoamine transporters. J Neurosci 1995; 15:6179-88.
16. Santiago M, Machado A, Cano J. Dopamine Release and Its Regulation in the CNS. In: Stone T, ed. CNS Neurotransmitters and Neuromodulators: Dopamine. Salem, MA: CRC Press 1996; 41-64.
17. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25.
18. Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol 2005; 521:86-94.
19. Laurenzana EM, Byrnes-Blake KA, Milesi-Halle A, Gentry WB, Williams DK, Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos 2003; 31:1320-6.
20. Smith TW, Haber E, Yeatman L, Butler VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294:797-800.
21. Caldwell J. Amphetamines and Related Stimulants: Chemical, Biological, and Sociological Aspects. Boca Raton, FL: CRC Press 1980.
22. Marquart G, Di Stefano V, Ling L. Pharmacological effects of (+/-),(S)- and (R)MDA. In: Stillman R, Willette R, eds. The Psychopharmacology of Hallucinogens. NY: Pergamon Press 1978; 85-104.
23. Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol 2001; 1:329-38.
24. Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci USA 2000; 97:6202-6.
25. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000; 148:251-62.
26. Kantak KM, Collins SL, Bond J, Fox BS. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl) 2001; 153:334-40.
27. Carrera MR, Ashley JA, Wirsching P, Koob GF, Janda KD. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 2001; 98:1988-92.
28. Koetzner L, Deng S, Sumpter TL, Weisslitz M, Abner RT, Landry DW, et al. Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. J Pharmacol Exp Ther 2001; 296:789-96.
29. LeSage MG, Keyler DE, Hieda Y, Collins G, Burroughs D, Le C, et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl) 2006; 184:409-16.
30. Roiko SA, Harris AC, Keyler DE, Lesage MG, Zhang Y, Pentel PR. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J Pharmacol Exp Ther 2008; 325:985-93.
31. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20:1196-204.
32. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58:158-64.
33. Cerny EH, Cerny T. Anti-nicotine abuse vaccines in the pipeline: an update. Expert Opin Investig Drugs 2008; 17:691-6.
34. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 2008; 3:2547.
35. Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, et al. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther 2007; 322:30-9.
36. Peterson EC, Laurenzana EM, Atchley WT, Hendrickson HP, Owens SM. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J Pharmacol Exp Ther 2008; 325:124-33.
37. Laurenzana EM, Gunnell MG, Gentry WB, Owens SM. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J Pharmacol Exp Ther 2003; 306:1092-8.
38. Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol 2003; 3:957-70.
39. Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, et al. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 2006; 6:968-77.
40. Keyler DE, Roiko SA, Benlhabib E, LeSage MG, St. Peter JV, Stewart S, et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 2005; 33:1056-61.
41. Malin DH, Lake JR, Lin A, Saldana M, Balch L, Irvin ML, et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001; 68:87-92.
42. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65:191-8.
43. Malin DH, Alvarado CL, Woodhouse KS, Karp H, Urdiales E, Lay D, et al. Passive immunization against nicotine attenuates nicotine discrimination. Life Sci 2002; 70:2793-8.
44. McMillan DE, Hardwick WC, Li M, Gunnell MG, Carroll FI, Abraham P, et al. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther 2004; 309:1248-55.
45. McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav Pharmacol 2002; 13:465-73.
46. Bazin-Redureau MI, Renard CB, Scherrmann JM. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab′)2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 1997; 49:277-81.
47. Daniels JR, Wessinger WD, Hardwick WC, Li M, Gunnell MG, Hall CJ, et al. Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons. Psychopharmacology (Berl) 2006; 185:36-44.
48. Gorelick DA, Wilkins JN, Wong C. Diagnosis and treatment of chronic phencyclidine (PCP) abuse. NIDA Res Monogr 1986; 64:218-28.
49. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 1993; 21:717-23.
50. Mendelson J, Jones RT, Upton R, Jacob P, 3rd. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 1995; 57:559-68.
51. Leshner AI. Science-based views of drug addiction and its treatment. JAMA 1999; 282:1314-6.
52. Brecht ML, von Mayrhauser C, Anglin MD. Predictors of relapse after treatment for methamphetamine use. J Psychoactive Drugs 2000; 32:211-20.
53. Cofta-Woerpel L, Wright KL, Wetter DW. Smoking cessation 3: multicomponent interventions. Behav Med 2007; 32:135-49.
54. Dale LC, Ebbert JO, Hays JT, Hurt RD. Treatment of nicotine dependence. Mayo Clin Proc 2000; 75:1311-6.
55. Grimshaw G, Stanton A. Tobacco cessation interventions for young people. Cochrane Database Syst Rev: The Cochrane Collaboration. John Wiley & Sons 2008; 4.
56. NIDA. Principles of Drug Addiction Treatment. Bethesda, MD: National Institute on Drug Abuse, National Institutes of Health 1999.
57. Cho AK. Ice: A new dosage form of an old drug. Science 1990; 249:631-4.
58. Schulhafer EP, Verma RS. Acquired immunodeficiency syndrome: molecular biology and its therapeutic intervention (review). In vivo 1989; 3:61-78.
59. Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci 2003; 73:129-40.
60. Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 2000; 292:831-7.
61. Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 2003; 461:119-28.
62. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005; 41:107-27.
63. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803-43.
64. Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharm 1990; 9:509-29.
65. Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos 2006; 34:906-12.
66. Hudson PJ. Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 1999; 11:548-57.
67. Hudson PJ, Kortt AA. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 1999; 231:177-89.
68. Lee LS, Conover C, Shi C, Whitlow M, Filpula D. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem 1999; 10:973-81.
69. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54:531-45.
70. Urbina A, Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis 2004; 38:890-4.
71. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991; 265:1152-4.
72. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann N Y Acad Sci 1992; 654:160-70.